Dr. Tuttle discussing diabetic CKD and benefits of relatively new med Finerenone #AACE2022
#diabetes is responsible for half of #CKD. CKD worsens CVD risk. 90% die from other cause before reaching ESRD #AACE2022 #endotwitter
Mineralocorticoid receptors increase inflammation and fibrosis --- blocking them decreases this (ie. Finerenone)
Finerenone clinical trials with positive results. Fidelio with #CVD outcome of 13% reduction, 23% reduction in kidney disease reduction #AACE2022
Finerenone dosing depending on eGFR, monitor potassium
#KDIGO updating this year for #CKD- should be published in the next few months. "harmonized" recommendations with ADA and AACE. SGLT2i and ARB/ACEi first line therapy. MRA and/or GLP1-RA for next line targeted therapy #aace2022
We aren't checking enough for albuminuria -- only 30-40% best picture -- 10% screening is the avg. We are also not treating them enough!
SGLT2i can decrease potassium so using with MRA can improve outcomes and decrease unwanted side effects
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.